Somatostatin Drugs Unexpectedly Bind to the GH Secretagogue Receptor Too
Somatostatin octapeptide drugs (lanreotide, octreotide, vapreotide) unexpectedly bound to GHRP receptors in the human pituitary, revealing cross-talk between the somatostatin and GH secretagogue receptor systems.
Quick Facts
What This Study Found
Somatostatin octapeptides (lanreotide, octreotide, vapreotide) showed significant binding to GHRP receptors in human pituitary membranes, revealing unexpected cross-reactivity between somatostatin and GH secretagogue receptor systems.
Key Numbers
How They Did This
In-vitro binding study using radiolabeled ligands on human pituitary membranes. Binding competition between somatostatin analogs, SRIF-14, and GHRP compounds at both SRIF and GHRP receptor subtypes.
Why This Research Matters
Millions of patients take somatostatin analogs for acromegaly and neuroendocrine tumors. Cross-binding to GHRP receptors could explain unexpected clinical effects or drug interactions.
The Bigger Picture
Receptor cross-reactivity is common but underappreciated. When clinical drugs bind to unintended receptors, it creates both unexpected effects and potential therapeutic opportunities.
What This Study Doesn't Tell Us
In-vitro binding on tissue membranes. Clinical significance of the cross-binding is uncertain. Binding doesn't prove functional activation or inhibition at GHRP receptors.
Questions This Raises
- ?Does somatostatin analog GHRP receptor binding contribute to their clinical effects?
- ?Could this cross-reactivity explain inconsistencies in acromegaly treatment?
- ?Should patients on somatostatin analogs avoid GH secretagogues?
Trust & Context
- Key Stat:
- Unexpected cross-binding Three commonly used somatostatin drugs bound GHRP receptors — a receptor system they weren't designed to target
- Evidence Grade:
- Preliminary in-vitro binding evidence in human pituitary tissue, providing clear cross-reactivity data but uncertain clinical significance.
- Study Age:
- Published in 2001. The interaction between somatostatin and ghrelin receptor systems continues to be studied for clinical implications.
- Original Title:
- Somatostatin octapeptides (lanreotide, octreotide, vapreotide, and their analogs) share the growth hormone-releasing peptide receptor in the human pituitary gland.
- Published In:
- Endocrine, 14(1), 29-33 (2001)
- Authors:
- Deghenghi, R(11), Papotti, M(8), Ghigo, E(14), Muccioli, G, Locatelli, V
- Database ID:
- RPEP-00662
Evidence Hierarchy
Frequently Asked Questions
Why does it matter that somatostatin drugs bind GHRP receptors?
Somatostatin analogs are prescribed to suppress GH (for acromegaly) and hormone-secreting tumors. If they also bind GHRP receptors, their effects are more complex than assumed — potentially explaining variable treatment responses.
Should patients be concerned?
Not necessarily, but it's worth knowing. The cross-binding may actually contribute to these drugs' overall effectiveness. It does mean combining somatostatin analogs with GH secretagogues requires careful consideration.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00662APA
Deghenghi, R; Papotti, M; Ghigo, E; Muccioli, G; Locatelli, V. (2001). Somatostatin octapeptides (lanreotide, octreotide, vapreotide, and their analogs) share the growth hormone-releasing peptide receptor in the human pituitary gland.. Endocrine, 14(1), 29-33.
MLA
Deghenghi, R, et al. "Somatostatin octapeptides (lanreotide, octreotide, vapreotide, and their analogs) share the growth hormone-releasing peptide receptor in the human pituitary gland.." Endocrine, 2001.
RethinkPeptides
RethinkPeptides Research Database. "Somatostatin octapeptides (lanreotide, octreotide, vapreotid..." RPEP-00662. Retrieved from https://rethinkpeptides.com/research/deghenghi-2001-somatostatin-octapeptides-lanreotide-octreotide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.